Kathryn (Kate) Falberg
Ms. Falberg most recently served as Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals PLC from 2009 to 2014, during which time the market capitalization of Jazz increased from approximately $200 million to approximately $9 billion. From 1995 to 2001, Ms. Falberg was with Amgen Inc., where she served as Senior Vice President, Finance and Strategy, Chief Financial Officer, and before that as Vice President, Controller and Chief Accounting Officer, and Vice President, Treasurer. During this time, Amgen’s sales grew from approximately $1.6 billion to approximately $4 billion and its market capitalization increased from approximately $8 billion to approximately $75 billion. Ms. Falberg currently serves on the board of directors and is the Audit Committee Chair at Ariosa Diagnostics, a medical diagnostics company; at Halozyme Therapeutics, Inc., a biopharmaceutical company; and at Medivation, Inc., a biopharmaceutical company.